Literature DB >> 27575911

Comparison of Lung Clearance Index and Magnetic Resonance Imaging for Assessment of Lung Disease in Children with Cystic Fibrosis.

Mirjam Stahl1,2,3, Mark O Wielpütz4,3,5, Simon Y Graeber1,2,3, Cornelia Joachim1,2,3, Olaf Sommerburg1,2,3, Hans-Ulrich Kauczor4,3, Michael Puderbach5,6, Monika Eichinger3,5,6, Marcus A Mall1,2,3.   

Abstract

RATIONALE: Early onset and progression of lung disease in children with cystic fibrosis (CF) indicates that sensitive noninvasive outcome measures are needed for diagnostic monitoring and early intervention clinical trials. The lung clearance index (LCI) and chest magnetic resonance imaging (MRI) were shown to detect early lung disease in CF; however, the relationship between the two measures remains unknown.
OBJECTIVES: To correlate the LCI with abnormalities detected by MRI and compare the sensitivity of the two techniques to detect responses to therapy for pulmonary exacerbations in children with CF.
METHODS: LCI determined by age-adapted multiple breath washout techniques and MRI studies were performed in 97 clinically stable children with CF across the pediatric age range (0.2-21.1 yr). Furthermore, LCI (n = 26) or MRI (n = 10) were performed at the time of pulmonary exacerbation and after antibiotic therapy. MRI was evaluated using a dedicated morphofunctional score.
MEASUREMENTS AND MAIN RESULTS: The LCI correlated with the global MRI score as well as MRI-defined airway wall abnormalities, mucus plugging, and abnormal lung perfusion in infants and toddlers (P < 0.05 to P < 0.001) and in older children (P < 0.001) with CF. LCI and MRI were sensitive to detect response to antibiotic therapy for pulmonary exacerbations.
CONCLUSIONS: Our results indicate that LCI and MRI may be useful complementary tools for noninvasive monitoring and as quantitative endpoints in early intervention trials in children with CF. In this context, MRI enables detection of disease heterogeneity, including regional mucus plugging associated with abnormal lung perfusion in early CF lung disease. Clinical trial registered with www.clinicaltrials.gov (NCT 02270476).

Entities:  

Keywords:  cystic fibrosis; lung clearance index; lung disease; magnetic resonance imaging; noninvasive monitoring

Mesh:

Year:  2017        PMID: 27575911     DOI: 10.1164/rccm.201604-0893OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  32 in total

Review 1.  Ten years of chest MRI for patients with cystic fibrosis : Translation from the bench to clinical routine.

Authors:  Patricia Leutz-Schmidt; Monika Eichinger; Mirjam Stahl; Olaf Sommerburg; Jürgen Biederer; Hans-Ulrich Kauczor; Michael U Puderbach; Marcus A Mall; Mark O Wielpütz
Journal:  Radiologe       Date:  2019-12       Impact factor: 0.635

2.  A two-center analysis of hyperpolarized 129Xe lung MRI in stable pediatric cystic fibrosis: Potential as a biomarker for multi-site trials.

Authors:  Marcus J Couch; Robert Thomen; Nikhil Kanhere; Raymond Hu; Felix Ratjen; Jason Woods; Giles Santyr
Journal:  J Cyst Fibros       Date:  2019-03-25       Impact factor: 5.482

3.  Regional Structure-Function in Cystic Fibrosis Lung Disease Using Hyperpolarized 129Xe and Ultrashort Echo Magnetic Resonance Imaging.

Authors:  Robert P Thomen; Laura L Walkup; David J Roach; Nara Higano; Andrew Schapiro; Alan Brody; John P Clancy; Zackary I Cleveland; Jason C Woods
Journal:  Am J Respir Crit Care Med       Date:  2020-07-15       Impact factor: 21.405

Review 4.  Novel Imaging Approaches in Systemic Sclerosis-Associated Interstitial Lung Disease.

Authors:  Sydney B Montesi; Peter Caravan
Journal:  Curr Rheumatol Rep       Date:  2019-04-25       Impact factor: 4.592

5.  Changes in magnetic resonance imaging scores and ventilation inhomogeneity in children with cystic fibrosis pulmonary exacerbations.

Authors:  Hartmut Grasemann; Pierluigi Ciet; Reshma Amin; Nancy McDonald; Michelle Klingel; Harm A W M Tiddens; Felix Ratjen; Lars Grosse-Wortmann
Journal:  Eur Respir J       Date:  2017-08-24       Impact factor: 16.671

6.  New severity assessment in cystic fibrosis: signal intensity and lung volume compared to LCI and FEV1: preliminary results.

Authors:  Sabrina Fleischer; Mareen Sarah Kraus; Sergios Gatidis; Winfried Baden; Andreas Hector; Dominik Hartl; Ilias Tsiflikas; Juergen Frank Schaefer
Journal:  Eur Radiol       Date:  2019-11-14       Impact factor: 5.315

Review 7.  Question 3: Can we diagnose asthma in children under the age of 5 years?

Authors:  C L Yang; J M Gaffin; D Radhakrishnan
Journal:  Paediatr Respir Rev       Date:  2018-10-24       Impact factor: 2.726

8.  Progression of Lung Disease in Preschool Patients with Cystic Fibrosis.

Authors:  Sanja Stanojevic; Stephanie D Davis; George Retsch-Bogart; Hailey Webster; Miriam Davis; Robin C Johnson; Renee Jensen; Maria Ester Pizarro; Mica Kane; Charles C Clem; Leah Schornick; Padmaja Subbarao; Felix A Ratjen
Journal:  Am J Respir Crit Care Med       Date:  2017-05-01       Impact factor: 21.405

9.  Gene Therapy for Respiratory Diseases: Progress and a Changing Context.

Authors:  Eric W F W Alton; A Christopher Boyd; Jane C Davies; Deborah R Gill; Uta Griesenbach; Tracy E Harman; Stephen Hyde; Gerry McLachlan
Journal:  Hum Gene Ther       Date:  2020-09       Impact factor: 5.695

Review 10.  The future of cystic fibrosis care: a global perspective.

Authors:  Scott C Bell; Marcus A Mall; Hector Gutierrez; Milan Macek; Susan Madge; Jane C Davies; Pierre-Régis Burgel; Elizabeth Tullis; Claudio Castaños; Carlo Castellani; Catherine A Byrnes; Fiona Cathcart; Sanjay H Chotirmall; Rebecca Cosgriff; Irmgard Eichler; Isabelle Fajac; Christopher H Goss; Pavel Drevinek; Philip M Farrell; Anna M Gravelle; Trudy Havermans; Nicole Mayer-Hamblett; Nataliya Kashirskaya; Eitan Kerem; Joseph L Mathew; Edward F McKone; Lutz Naehrlich; Samya Z Nasr; Gabriela R Oates; Ciaran O'Neill; Ulrike Pypops; Karen S Raraigh; Steven M Rowe; Kevin W Southern; Sheila Sivam; Anne L Stephenson; Marco Zampoli; Felix Ratjen
Journal:  Lancet Respir Med       Date:  2019-09-27       Impact factor: 30.700

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.